✨ Free AI Report
Spero Therapeutics, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Spero Therapeutics, Inc.
Company Research

Spero Therapeutics, Inc.: Business Overview, Financials & Competitive Analysis

Spero Therapeutics is dedicated to delivering differentiated medicines to help patients suffering from rare diseases and multidrug-resistant (MDR) bacterial infections. The company has achieved a significant milestone...

Analyst-debate audio for Spero Therapeutics, Inc.

AskCyborg analysts argue the bull and bear cases for Spero Therapeutics, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
7/ 10Strong

Cyborg Score thesis

Clinical-stage biotech with validated mechanism (tebipenem HBr) and pharma partnership backing offers compelling risk-adjusted...

Read the full analyst-debate transcript →
Industry Biopharmaceutical Development - Specialty Focus (MDR Infections & Rare Diseases)
1 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest Spero Therapeutics, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Spero Therapeutics, Inc. Overview

Pro stress-test →

Spero Therapeutics is dedicated to delivering differentiated medicines to help patients suffering from rare diseases and multidrug-resistant (MDR) bacterial infections. The company has achieved a significant milestone with its lead asset tebipenem HBr, an oral carbapenem candidate that represents a potential first-in-class treatment for complicated urinary tract infections.

Strategic Profile

Pro stress-test →

In May 2025, Spero and GSK announced that the PIVOT-PO Phase 3 trial evaluating tebipenem HBr has met its primary endpoint and will stop early for efficacy. The company's partnership with GSK provides development and commercialization support, positioning Spero as a specialized biopharmaceutical developer focused on high unmet medical needs in niche therapeutic areas where approved options are limited.

Competitive Landscape

Pro stress-test →

Spero operates in the niche antibiotic development space, competing with other specialized biotech firms developing novel treatments for MDR infections. The company's focus on oral carbapenems and rare diseases positions it distinctly from larger pharmaceutical firms, with primary competitive pressure from other clinical-stage developers and potential large pharma entrants. The partnership with GSK provides differentiated access to development and commercial resources.

Industry Context

Spero Therapeutics, Inc. operates in Biopharmaceutical Development - Specialty Focus (MDR Infections & Rare Diseases).

Key facts

Founded: 2013 · Headquarters: Cambridge, MA, US

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Spero Therapeutics, Inc..

  • Tebipenem HBr Phase 3 success positions as potential first oral carbapenem for cUTIs, addressing critical treatment gap for patients avoiding hospitalization
  • GSK partnership provides substantial development and commercialization credibility with established pharma commercialization infrastructure
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • May 2025PIVOT-PO Phase 3 trial for tebipenem HBr met primary endpoint with early stopping for efficacy
  • October 2025Efficacy and safety results from pivotal phase 3 PIVOT-PO trial presented at IDWeek conference
  • +1 moreTrack every material event for Spero Therapeutics, Inc. as it happens. Explore monitoring →
Get alerted when Spero Therapeutics, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Investigational antibiotics for MDR infectionsDeveloping alternative solutions for multidrug-resistant bacterial infections→

Compare Spero Therapeutics, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Spero Therapeutics, Inc. operates in Biopharmaceutical Development - Specialty Focus (MDR Infections & Rare Diseases). See how the rest of the sector scores on the Cyborg framework.

Browse Biopharmaceutical Development - Specialty Focus (MDR Infections & Rare Diseases) research →
NEW · MCP server

Ask your AI assistant about Spero Therapeutics, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Spero Therapeutics, Inc. and its top competitor on Cyborg Score”
“What did Spero Therapeutics, Inc. do this quarter?”
“Is Spero Therapeutics, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does Spero Therapeutics, Inc. do?+
Spero Therapeutics is dedicated to delivering differentiated medicines to help patients suffering from rare diseases and multidrug-resistant (MDR) bacterial infections. The company has achieved a significant milestone...
What is Spero Therapeutics, Inc.'s Cyborg Score?+
Spero Therapeutics, Inc. has a Cyborg Score of 7/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Spero Therapeutics, Inc.'s main competitors?+
Named competitors include Investigational antibiotics for MDR infections. The full competitive landscape is in the AskCyborg report.
How can I get the full Spero Therapeutics, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Spero Therapeutics, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Spero Therapeutics, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.